Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIxico Regulatory News (IXI)

Share Price Information for Ixico (IXI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 7.00
Bid: 6.75
Ask: 7.25
Change: 0.00 (0.00%)
Spread: 0.50 (7.407%)
Open: 7.00
High: 7.00
Low: 7.00
Prev. Close: 7.00
IXI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

28 Mar 2008 15:24

Phytopharm PLC28 March 2008 NOTIFICATION OF TRANSACTIONS OF DIRECTORS, PERSONS DISCHARGING MANAGERIALRESPONSIBILITY OR CONNECTED PERSONS This form is intended for use by an issuer to make a RIS notification requiredby DR 3.1.4R(1). (1) An issuer making a notification in respect of a transaction relating to the shares or debentures of the issuer should complete boxes 1 to 16, 23 and 24. (2) An issuer making a notification in respect of a derivative relating to the shares of the issuer should complete boxes 1 to 4, 6, 8, 13, 14, 16, 23 and 24. (3) An issuer making a notification in respect of options granted to a director/person discharging managerial responsibilities should complete boxes 1 to 3 and 17 to 24. (4) An issuer making a notification in respect of a financial instrument relating to the shares of the issuer (other than a debenture) should complete boxes 1 to 4, 6, 8, 9, 11, 13, 14, 16, 23 and 24. Please complete all relevant boxes in block capital letters. 1. Name of the issuer PHYTOPHARM PLC 2. State whether the notification relates to (i) a transaction notified inaccordance with DR 3.1.4R(1)(a); or (ii) DR 3.1.4(R)(1)(b) a disclosure made inaccordance with section 324 (as extended by section 328) of the Companies Act1985; or (iii) both (i) and (ii) (III) BOTH (I) AND (II) 3. Name of person discharging managerial responsibilities/director DR DARYL REES, CHIEF EXECUTIVE 4. State whether notification relates to a person connected with a persondischarging managerial responsibilities/director named in 3 and identify theconnected person AS 3 ABOVE 5. Indicate whether the notification is in respect of a holding of the personreferred to in 3 or 4 above or in respect of a non-beneficial interest AS 3 ABOVE 6. Description of shares (including class), debentures or derivatives orfinancial instruments relating to shares OPTIONS OVER ORDINARY SHARES OF 1 PENCE EACH 7. Name of registered shareholders(s) and, if more than one, the number ofshares held by each of them 8 State the nature of the transaction 9. Number of shares, debentures or financial instruments relating to sharesacquired 10. Percentage of issued class acquired (treasury shares of that class shouldnot be taken into account when calculating percentage) 11. Number of shares, debentures or financial instruments relating to sharesdisposed 12. Percentage of issued class disposed (treasury shares of that class shouldnot be taken into account when calculating percentage) 13. Price per share or value of transaction 14. Date and place of transaction 15. Total holding following notification and total percentage holding followingnotification (any treasury shares should not be taken into account whencalculating percentage) 16. Date issuer informed of transaction If a person discharging managerial responsibilities has been granted options bythe issuer complete the following boxes 17 Date of grant 28 MARCH 2008 18. Period during which or date on which it can be exercised 28 MARCH 2011 to 27 MARCH 2018 19. Total amount paid (if any) for grant of the option NIL 20. Description of shares or debentures involved (class and number) 200,000 PHYTOPHARM PLC ORDINARY 1 PENCE SHARES 21. Exercise price (if fixed at time of grant) or indication that price is to befixed at the time of exercise 23.50 PENCE 22. Total number of shares or debentures over which options held followingnotification 1,478,559 23. Any additional information THE OPTION IS SUBJECT TO PERFORMANCE CONDITIONS MEASURING THE COMPANY'S TOTALSHAREHOLDER RETURN (TSR) AGAISNT THE TSR OF THE FTSE SMALLCAP INDEX COMMENCINGON THE GRANT DATE 24. Name of contact and telephone number for queries ZOE MCGOWAN 01480 437697 Name and signature of duly authorised officer of issuer responsible for makingnotification ZOE MCGOWAN Date of notification 28 March 2008 END This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
8th Mar 20227:00 amRNSContract worth circa £800k
14th Feb 20227:00 amRNSLaunch of IXIQ.Ai Deep learning AI-based platform
8th Feb 202212:30 pmRNSHolding(s) in Company
8th Feb 20227:00 amRNSContract award worth circa £1.0m
31st Jan 20227:00 amRNSAppointment of Senior Therapeutic Advisor
26th Jan 20227:00 amRNSDementia collaboration
21st Jan 20227:00 amRNSNon-Executive Director Appointment
20th Jan 202210:50 amRNSResult of AGM
20th Jan 20227:00 amRNSHuntington’s disease contract update
10th Jan 20227:00 amRNSGrant of share options
7th Dec 20217:00 amRNSFinancial Results for the year ended 30 Sept 2021
22nd Nov 20217:00 amRNSNotice of Results
1st Nov 20216:08 pmRNSHolding(s) in Company
1st Nov 20217:00 amRNSNew contract worth >£1.0m
20th Oct 20214:27 pmRNSContract update
18th Oct 20217:00 amRNSTrading Update for year ended 30 September 2021
22nd Sep 20217:00 amRNSNew contract worth >$750k
20th Sep 20217:00 amRNSPhase II HD contract with new client worth >$500K
8th Sep 20217:00 amRNSPhase I MSA contract award worth >$500k
6th Aug 20217:00 amRNSTrading Update
23rd Jun 20213:32 pmRNSIssue of Equity
21st Jun 20212:31 pmRNSHolding(s) in Company
15th Jun 20217:00 amRNSFurther investment in Ixico plc
11th Jun 202111:35 amRNSHolding(s) in Company
25th May 20217:00 amRNSHalf yearly report to 31 March 2021
20th May 20217:00 amRNSPhase II Alzheimer’s disease contract award
19th May 20217:00 amRNSContract win for new neuroinflammatory disorder
11th May 20217:00 amRNSNotice of results
28th Apr 20217:00 amRNSContract win for new stroke study
26th Apr 20217:00 amRNSTrading update
19th Apr 20218:21 amRNSHolding(s) in Company
12th Apr 20214:00 pmRNSHolding(s) in Company
12th Apr 20217:00 amRNSInvestment in Ixico plc
1st Apr 20217:00 amRNSHolding(s) in Company
25th Mar 20219:14 amRNSPDMR Transaction
24th Mar 20219:05 amRNSSecond Price Monitoring Extn
24th Mar 20219:00 amRNSPrice Monitoring Extension
23rd Mar 20214:40 pmRNSSecond Price Monitoring Extn
23rd Mar 20214:35 pmRNSPrice Monitoring Extension
23rd Mar 20213:05 pmRNSHuntington’s disease Phase III contract updates
15th Mar 20214:41 pmRNSSecond Price Monitoring Extn
15th Mar 20214:35 pmRNSPrice Monitoring Extension
15th Mar 20212:06 pmRNSSecond Price Monitoring Extn
15th Mar 20212:00 pmRNSPrice Monitoring Extension
15th Mar 202111:06 amRNSSecond Price Monitoring Extn
15th Mar 202111:01 amRNSPrice Monitoring Extension
15th Mar 20217:00 amRNSCollaboration with Microsoft
10th Mar 20217:00 amRNSIXICO chosen for new Phase II AD study
2nd Mar 20217:00 amRNSIXICO selected by Cyclerion for a new AD study
1st Mar 20215:25 pmRNSExercise of Options; PDMR Dealing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.